HLB생명과학

067630KOSDAQ의료용품 및 기타 의약 관련제품 제조업

38.2 / 100

Reference Date: 2026-06-10

Financial Score13.5 / 40

News Sentiment17.7 / 25

Momentum3.0 / 20

Disclosure4.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Plunged 23.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Life Science operates four business divisions: Medicare, Biotech Development, Medical Device, and Energy, focusing on medical device manufacturing, pharmaceutical R&D, disposable syringe production, and solar EPC projects. Key clients include Abbott and Roche, and the company expanded its medical device market through the 2023 merger with Hwa Jin Medical and acquisition of Tinyco, which specializes in medical-grade nickel-titanium alloys.

Number of Employees

180people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.194.0Point

PBR

1.27Industry Average 1.304.0Point

In line with industry avg

ROE

-28.70Industry Average -4.893.5Point

5.9x industry avg (excellent)

Debt Ratio

20.67Industry Average 6.860.0Point

3.0x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼25.5% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲5.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.8% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 5Neutral 2Negative 1Average Sentiment Score 70.6

Positive
HLB생명과학R&D, 과기정통부 ‘AIx바이오혁신거점’ 참여…AI 신약...
HLB생명과학이 과기정통부의 AI 혁신 연구거점에 참여하여 AI 신약 개발 역량 강화를 위한 핵심 프로젝트에 합류함으로써 긍정적인 시장 반응을 이끌어낼 것으로 예상됩니다.
Neutral
HLB생명과학, 100억 규모 전환사채 발행 결정
HLB생명과학이 100억원 규모의 CB 발행 결정을 공시했으나, 구체적인 시장 영향은 제한적이다.
Positive
"항암제 후보물질, AI로 발굴"…정부 'AI 신약 개발 사업' 선정된...
HLB생명과학이 정부 주도 AI 신약 개발 프로젝트에 참여하여 기술적 우위와 신약 개발 가능성을 강화했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,105Won52-week high 5,94052-week low 3,105

1-month return0.0Point

1m -23.14% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 5Negative 2

Neutral증권발행결과(자율공시) (제17회차 CB)2026-06-08
Neutral전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)2026-05-29
Neutral주요사항보고서(전환사채권발행결정)2026-05-28
Neutral교환가액의조정 (제16회차)2026-05-21
Neutral분기보고서 (2026.03)2026-05-15